ADEL 001
Alternative Names: ADEL-001Latest Information Update: 24 May 2024
At a glance
- Originator Aptadel Therapeutics
- Class Antineoplastics; Nucleotide aptamers; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 15 Apr 2024 Early research in Solid tumours in Spain, as of April 2024 (Aptadel Therapeutics pipeline, April 2024)